Dr Meshinchi gives a presentation to the American Society of Hematology in San Diego December 2023.

He reports on the status of 25 patients who have received STRO-002 as part of their treatment for GLIS2 AML.

Sutro Biopharma

“It is clear from the data that luvelta is providing an ongoing and promising impact on the lives of infants and young children with this rare leukemia,” said Bill Newell, Sutro’s Chief Executive Officer. “

Between August 2021 and July 2022, 16 patients received STRO-002. Click on the ASH report below.